101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Investor Presentation
Financial Results, Press Release
Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Tenax Therapeutics Enters Supply Agreement with Orion Corporation
Executive Employment Agreement Amendments for Tenax Therapeutics
Stockholder Meeting Results - Directors Elected at Tenax Therapeutics
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report